History

Discovered in 1973 by Loren Pickart, who isolated the activity from human plasma albumin while studying why young blood helped aged liver tissue function better. The active factor was the tripeptide glycyl-L-histidyl-L-lysine (GHK), and by 1977 its activity was tied to its copper complex, GHK-Cu. Natural plasma levels fall with age. Pickart and later researchers developed it for wound healing and skin regeneration, and it became a staple "copper peptide" cosmetic ingredient.

GHK-Cu is one of the oldest and most-hyped “regenerative” peptides, marketed for skin aging, hair, and wound healing. The lab science is genuinely interesting; the human evidence is thinner and less independent than the marketing suggests.

What it is

GHK-Cu is the tripeptide glycyl-L-histidyl-L-lysine bound to a copper ion. The peptide occurs naturally in human plasma, saliva, and urine, where its levels decline with age. It binds copper with high affinity, which is central to its proposed biological activity. In cosmetics it appears under the INCI name copper tripeptide-1. It is sold three main ways: as a topical serum or cream, as an injectable from compounding pharmacies, and as research-grade powder.

The claims

Vendors and clinics claim GHK-Cu boosts collagen and elastin, smooths wrinkles, tightens skin, accelerates wound healing, regrows hair, reduces inflammation, and acts as a broad “anti-aging” or even systemic regenerative agent. Some claims extend to gene-level “reprogramming” of cells.

What the evidence actually shows

The mechanistic and lab data are substantial. In cell and animal studies GHK-Cu stimulates fibroblasts, modulates collagen and metalloproteinase activity, and shifts the expression of thousands of genes. A widely cited review by the peptide’s discoverer reports that it can up- or down-regulate a large fraction of human genes in cultured cells. These are real findings, but they are mostly in vitro and in rodents, and “changes gene expression in a dish” is not the same as a clinical benefit.

Human data exist but are limited. The strongest are several small, roughly 12-week, placebo-controlled facial cosmetic trials (on the order of dozens of women each) reporting modest improvements in firmness, density, fine lines, and clarity, plus older wound-healing reports in diabetic ulcers and post-surgical skin. Importantly, much of the foundational human and review literature was produced by the peptide’s discoverer or industry-linked groups, and large, independent randomized trials are absent. There is also a delivery problem: GHK-Cu is a charged, hydrophilic molecule, and studies disagree on how much of it crosses intact skin. One in vitro penetration study reported that meaningful amounts could be delivered through skin layers, while a 2025 review concluded that its skin permeation has not been well characterized and that formulation (for example, liposomal encapsulation) likely matters a great deal. For injectable or systemic anti-aging use, meaningful human outcome data are essentially nonexistent.

Legal and regulatory status

GHK-Cu is not an FDA-approved drug for any use. As a topical cosmetic ingredient it is widely sold, but cosmetics cannot legally claim to treat disease. The compounding picture shifted in 2026: the FDA removed non-injectable GHK-Cu from its Category 1 list and injectable GHK-Cu from its Category 2 “do not compound” list. Reporting from FDA-focused law firms stresses that both moves happened because the underlying nominations were withdrawn — not because of any affirmative finding of safety or efficacy — and that GHK-Cu is slated for a Pharmacy Compounding Advisory Committee (PCAC) review before the end of February 2027. Crucially, removal from these lists is not the same as approval, and does not by itself make GHK-Cu eligible for legal compounding. It is not a green light. WADA does not name GHK-Cu on its 2026 Prohibited List, but a substance with no regulatory approval can still fall under the “non-approved substances” catch-all that is prohibited at all times; athletes should not assume it is permitted.

Safety

Topical GHK-Cu is generally well tolerated, with occasional irritation. Injectable and systemic safety in humans is poorly characterized — there are no large safety trials, sterility and dosing depend entirely on the source, and copper has a real toxic ceiling, so chronic systemic loading is a genuine unknown. Avoid in pregnancy and in copper-related conditions such as Wilson’s disease. Nothing here is medical advice.

Bottom line

GHK-Cu has a strong mechanistic story and some encouraging but small, short, industry-associated topical trials — promising, not proven, and far weaker for injected use. Treat it as a cosmetic ingredient with early human support, not a validated therapy.

Evidence grade: Preliminary human.

GHK-Cu (Copper Peptide): What the Evidence Actually Shows